Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors have?
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors has 520 citations in the OpenAlex counts ScholarIQ stores.
When was Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors published?
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors has 2006 year in the ScholarIQ index.
What is the open-access status of Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors?
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors has closed oa status in the ScholarIQ index.
What is the DOI of Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors?
The DOI for Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors is on the source record.
What is the PMID of Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors?
The PMID for Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors is on the source record.
What is the OpenAlex record for Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors?
The OpenAlex for Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors is on the source record.